Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 17/20 | 0.72 |
| ▸ | GNA15 | P30679 | 1/20 | 0.67 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.61 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.61 |
| ▸ | RXRA | P19793 | 1/20 | 0.61 |
| ▸ | RXRB | P28702 | 1/20 | 0.61 |
| ▸ | RXRG | P48443 | 1/20 | 0.61 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.60 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9966870 | 0.90 | FFAR1 (0.68) | FFAR1GNA15FFAR4 | |
| SCHEMBL12577973 | 0.90 | MAOB (0.69) | FFAR1GNA15FFAR4 | |
| SCHEMBL1635007 | 0.84 | FFAR1 (1.00) | FFAR1FFAR4 | |
| SCHEMBL9935151 | 0.83 | FFAR1 (1.00) | FFAR1GNA15 | |
| SCHEMBL13951781 | 0.82 | MAOB (0.78) | NR4A2RXRARXRBRXRGNR4A1 | |
| SCHEMBL15153440 | 0.82 | FFAR1 (0.64) | FFAR1GNA15FFAR4 | |
| SCHEMBL15485443 | 0.82 | FFAR1 (0.68) | FFAR1GNA15FFAR4 | |
| SCHEMBL28481481 | 0.82 | FFAR1 (1.00) | FFAR1GNA15FFAR4 | |
| SCHEMBL28476384 | 0.81 | FFAR1 (1.00) | FFAR1 | |
| SCHEMBL9934278 | 0.80 | FFAR1 (0.83) | FFAR1GNA15FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157459-A1 | NOVEL 3-HYDROXY-5-ARYLISOTHIAZOLE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157459-A1 | NOVEL 3-HYDROXY-5-ARYLISOTHIAZOLE DERIVATIVE | GPR119, GPR27, NR0B1 | FFAR1 39/4885GNA15 667/4885FFAR4 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.